Clinical Principles For Novel Antitumor Drugs: 2024 Guidance
China's 2024 guidance promotes precise, safe use of novel anticancer drugs based on pathology, biomarker testing, and approved indications.
Overview
China's 2024 clinical guidance outlines principles for using novel anticancer drugs, including targeted agents and immunotherapies. The document spans many tumor types and drug classes.
A central theme is that these medicines must be used precisely, safely, and only when evidence supports benefit.
Fundamental Principles
Treatment requires a confirmed pathologic diagnosis, often with biomarker testing to select the right drug. Therapy must follow approved indications for each cancer and agent.
Clinicians choose agents rationally and adjust use for special patient situations. Close attention to drug-related side effects protects patients.
Targeted And Immune Therapies
Targeted drugs act on specific mutations or pathways, such as EGFR, ALK, and blood-cancer drivers. Immune therapies engage the body's defenses against tumors.
Hematology agents include tyrosine kinase inhibitors, proteasome inhibitors, and cell-based therapies for leukemias and lymphomas.
Safety And Monitoring
Adverse reactions range from mild to life-threatening and need active surveillance. Teams should report, manage, and document toxicity according to each drug's profile.
